Functional kratom dependence: quitting while you keep your job

At a glance: top concerns for working people

Key Takeaways

• Functional does not mean fine. Dosing to stay ahead of withdrawal while holding a job is not stability; it is maintained dependence that quietly deepens and costs more over time.
• You can usually get treated without stopping work. Outpatient telehealth buprenorphine treatment is designed for people with jobs. Once stabilized, it supports function rather than impairing it.
• You have privacy and, in most cases, legal protection. Whether to tell your employer is your decision. People in supervised MAT for OUD are generally protected from employment discrimination under the ADA.
• Active dependence is the bigger career risk. Escalating cost, declining performance, and missed days due to withdrawal threaten a job more than getting treatment does.

The functional trap: why a job makes it easy to postpone

The internal logic is recognizable to most people in this situation: "I'm showing up, I'm getting things done, I'm not like someone with a real problem." That thought is the reason functional dependence tends to run longer and get deeper than other patterns before anything changes.

What is actually happening underneath a functional routine: the person is dosing on a schedule to prevent withdrawal from appearing during work hours. The dose that accomplished that six months ago has grown. The cost has increased. Gaps in the schedule, a delayed delivery, an unexpected workday demand, produce anxiety or early withdrawal symptoms that compound whatever stress was already present.

The reframe worth sitting with: the fear is that treatment will disrupt the job. The more accurate picture is that untreated dependence is already disrupting it, through the cognitive bandwidth it consumes, the money it diverts, and the trajectory it is on. Concentration, emotional availability, and reliability tend to improve with stabilization, not to decline.

Can you keep working through treatment?

For the large majority of people with kratom or 7-OH dependence, yes.

Treatment is outpatient and telehealth-accessible. Buprenorphine treatment does not require a clinic stay. There are no daily dosing trips. Appointments, including initial evaluation and follow-up visits, can be scheduled before a work shift, over lunch, or in the evening. Telehealth visits are available in most states and take about as long as a pharmacy pickup.

The induction timing can usually be planned. The first day or two of induction involves the initial wait window and first dose, which some people prefer to schedule at the start of a weekend to minimize any disruption. After induction, the day-to-day experience of taking a daily sublingual film is not different from taking any other prescribed medication.

Stabilization supports function. Buprenorphine, taken as prescribed, does not produce sedation or intoxication at therapeutic doses. It stabilizes opioid receptors, which removes the oscillation between withdrawal and temporary relief that characterizes active dependence. Most people describe the stabilized state as being able to focus on work again, rather than quietly managing symptoms all day.

The clinical picture from the case literature is consistent with this: people treated for kratom and opioid use disorder with buprenorphine report improved daily functioning, not impaired functioning, once stabilized.

Your job, your privacy, and your legal rights

This section provides factual information about the legal landscape. It is not legal advice. The specific protections available to you depend on your employer, your state, and your role. For individualized legal questions, contact a legal aid organization or employment attorney.

ADA protections for people in treatment

The Americans with Disabilities Act (ADA) protects individuals with opioid use disorder from employment discrimination when they are in supervised treatment and not currently using drugs illegally. The EEOC has issued guidance specifically stating that people who are receiving medication-assisted treatment for OUD, including buprenorphine, are protected from disability discrimination under the ADA. The DOJ has issued parallel guidance confirming the same protections.

Key parameters of ADA protection:

The EEOC guidance specifically names buprenorphine and methadone as opioid medications whose prescribed use is protected. A person who tests positive for buprenorphine on an employer drug test and can document a valid prescription "may not be denied or fired from a job for this legal use of medication, unless they cannot do the job safely and effectively, or are disqualified under another federal law."

Privacy

Whether to disclose your treatment to your employer is your decision. The ADA includes medical confidentiality requirements that limit how employers may use and share health information. However, there are exceptions, and no law guarantees absolute privacy in all workplace contexts.

You are not required to disclose that you are in treatment in order to receive ADA protection, though in practice some protections require disclosure and a request for accommodation. An employment attorney or HR professional familiar with ADA procedures can advise on when and how disclosure may be appropriate in your situation.

Drug testing

Buprenorphine is not a target analyte on standard workplace drug panels or the DOT 5-panel. It does not produce a positive result on the opioid portion of standard immunoassay screens. Some employers' non-DOT drug panels do include buprenorphine as an add-on test. If buprenorphine appears in a test result and you have a valid prescription, documenting the prescription with the medical review officer (MRO) demonstrates legal use.

For a full discussion of drug testing and kratom, including the DOT panel, see Does 7-OH Show Up on a DOT Drug Test?.

Safety-sensitive and DOT-regulated roles

If your job is regulated by the DOT (commercial truck driving, airline piloting, railroad, transit, pipeline, or maritime work), additional rules apply. FMCSA medical examiners evaluate fitness for duty, and medication use is part of that assessment. Buprenorphine is no longer automatically disqualifying for CDL holders under current FMCSA guidance, but medical examiner discretion applies, and documentation of stability is important. The practical picture for safety-sensitive workers is covered in detail at Does 7-OH Show Up on a DOT Drug Test?.

Why not just tough it out at your desk

The cold-turkey option, stopping abruptly without medical support, peaks around days 2 to 4 with symptoms severe enough that working through them is nearly impossible for most people. That window of acute physical misery is exactly when relapse is most likely, because using brings immediate relief. For someone trying to hold a job, unsupported cold turkey creates the disruption they were trying to avoid, without the stabilization that follows successful treatment.

A clinician-guided approach with buprenorphine is substantially more work-compatible. The acute phase that makes cold turkey so disruptive largely does not occur. The person continues to function rather than losing several days to withdrawal symptoms and then returning to use anyway.

For most people with significant kratom or 7-OH dependence, outpatient MAT is the more work-compatible path. The disruption people fear from treatment is smaller than the disruption that continued active dependence is already causing.

Frequently Asked Questions

Can you work while taking Suboxone for kratom?

Yes. Buprenorphine at therapeutic doses does not cause sedation or intoxication. Most people who stabilize on buprenorphine describe improved concentration and reliability, not impaired function. The medication removes the daily management of withdrawal that active dependence requires, freeing up cognitive bandwidth that was previously consumed by dosing calculations and supply management.

Does my employer have to know I am in treatment?

No. Disclosure is your choice. People in supervised MAT for OUD are protected from employment discrimination under the ADA without necessarily having to disclose their treatment in advance, though some accommodation processes do involve disclosure. Whether and how to disclose is a personal and legal question that an employment attorney or HR professional familiar with ADA procedures can help you navigate. This article is not legal advice.

Will Suboxone show up on a drug test at work?

Buprenorphine is not a target analyte on standard workplace drug panels. It does not cause a positive result on the opioid portion of standard screens. Some expanded non-DOT employer panels do include buprenorphine. If it appears and you have a valid prescription, documenting the prescription with the MRO establishes legal use. For DOT-regulated roles, separate rules apply.

What if I am in a DOT-regulated job?

DOT-regulated workers face a more complex picture. FMCSA rules require medical examiners to evaluate fitness for duty, and buprenorphine is no longer automatically disqualifying under current guidance. However, examiner discretion applies, and documentation of stability from your prescriber matters. The DOT-specific piece has the detailed breakdown.

How do I start treatment without missing work?

The induction process, including the wait window and first dose, can often be scheduled around a weekend or days off. After induction, treatment is a daily sublingual film and periodic telehealth follow-up visits that can be scheduled to fit your schedule. A telehealth provider can evaluate you by video and, if appropriate, send a prescription to your pharmacy the same day you reach out. Learn how Bicycle Health's treatment works.